Disparities in blood cancer survival in the UK 2009–2019: national cohort studies
Joshua E. Allen, Rebecca A. Capel, Rebecca Thomas, Stephanie Smits et autres
0 citationsBJC Reports
Ceri Bygrave
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
80Publications signalées
544Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisCancer Treatment and PharmacologyAcute Myeloid Leukemia Research
Publications récentes
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
S Delimpasi, I Spicka, Jason P. Butler, DON A. STEVENS et autres
1 citationBritish Journal of Haematology
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients
Karthik Ramasamy, Kara‐Louise Royle, Robert Cicero, Ruth de Tute et autres
0 citationsBlood
Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma
Aristeidis Chaidos, Dimitrios Potolidis, Jessica Cornice, Holger W. Auner et autres
0 citationsBlood
Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network
Javier de la Rubia, Roman Hájek, Jiří Minařík, S. J. Martin et autres
0 citationsBlood
Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial
Rakesh Popat, Robert Cicero, Andrew Hall, Alexandra Welsh et autres
0 citationsBlood
Comparing Smouldering Myeloma High-Risk and Evolving Phenotype Definitions in the Prospective, Nationwide UK Cosmos Study
Daniel Hughes, Louise Ainley, Elise Rees, Conor Garrod-Ketchley et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Investigating the Role of the BAFF-APRIL System in Promoting Progression of Smouldering Myeloma (SMM)
Amatta Mirandari, Elise Rees, Louise Ainley, Emma J. Lyon et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Sociodemographic Inequalities in Blood Cancer Survival in Wales
Joshua E. Allen, Rebecca A. Capel, Diana R. Withrow, Rebecca Thomas et autres
0 citationsStudies in health technology and informatics
Single-cell profiling of human bone marrow reveals multiple myeloma progression is accompanied by an increase in CD56 bright bone marrow resident NK cells
Elise Rees, Isabella Sodi, Kane Foster, Louise Ainley et autres
2 citationsbioRxiv (Cold Spring Harbor Laboratory)
A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
Hannah Belcher, James M Duffell, Laura Williams, Ceri Bygrave
0 citationsBlood
Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Sarah Gooding, Kara‐Louise Royle, Mohammad H. Kazeroun, Robert Cicero et autres
0 citationsBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.